Scope of the Study
Bisphosphonates drug is used to treat and prevent bone-related conditions. Bisphosphonates drugs are expected to grow exponentially during the forecast period owing to the increasing demand for the prevention and treatment of osteoporosis in postmenopausal women and for the treatment of Pagetís disease of bone. Also in anticancer treatment particularly for metastatic bone cancer and multiple myeloma bisphosphonate drugs are used.
The market study is being classified by Type (Alendronate, Etidronate, Risedronate and Zoledronic Acid), by Application (Post-menopausal osteoporosis, Bone Loss caused by Cancer Treatment, Complex Regional Pain Syndrome and Paget's disease) and major geographies with country level break-up.
Sanofi-Aventis SA (France), Immunomedics, Inc. (United States), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Progenics Pharmaceuticals, Inc. (United States), EUSA Pharma, Inc. (United States), Cell Genesys Inc. (United States), Dendreon Corporation (United States), Amgen Inc. (United States), Medimmune, LLC (United States) and AstraZeneca PLC (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Abbott Laboratories (United States), Genentech Inc. (United States), ALZA Corporation (United States), Spectrum Pharmaceuticals, Inc. (United States) and GlaxoSmithKline Plc (United Kingdom).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Bisphosphonate Drug market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Bisphosphonate Drug market by Type, Application and Region.
On the basis of geography, the market of Bisphosphonate Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Geriatric Population and Changing Lifestyle Globally
- Increasing Expenditure in the Healthcare Industry
- Bisphosphonate Drug is Prescribed for Treatment of Osteoporosis
- High Cost associated with Drug
- Increasing Research and Development Activites related to Drugs
- Increasing Incidence of Menopausal in Women
- Increasing Awareness of Bisphosphonate Drug
- Side Effects of the Drug such as Nausea, Abdominal Pain and Loose Bowel Movements
Market Leaders and their expansionary development strategies
In October 2019, Lantheus Holdings, Inc and Progenics Pharmaceuticals, Inc. announced a definitive agreement for Lantheus to acquire Progenics in an all-stock transaction. The combination of Lantheus and Progenics forms an innovative company with a diversified diagnostic and therapeutics portfolio.
Key Target AudienceBisphosphonate Drug Manufacturers, Distributors/Traders/Wholesalers, Subcomponent Manufacturers, Industry Association and Downstream Vendors
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase